Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics insider sale disclosure: Freddy A. Jimenez, SVP & General Counsel and officer of Celldex Therapeutics, reported two open-market dispositions of common stock on 08/13/2025. He sold 341 shares at $23.9515 and 430 shares at $25.415. After these transactions he beneficially owned 34,962 shares. The filing notes 269 of the reported shares were acquired under the company’s 2004 Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
This Schedule 13G/A reports that Eventide Asset Management, LLC and two individuals, Finny Kuruvilla, M.D., Ph.D. and Robin C. John, each are associated with an aggregate beneficial ownership of 1,356,186 shares of Celldex Therapeutics common stock, representing 2.0% of the class. The filing cites the date of event requiring filing as 06/30/2025 and contains signatures dated 08/14/2025.
Eventide is reported with sole voting and sole dispositive power over 1,356,186 shares, while Kuruvilla and John are reported with shared voting and shared dispositive power over the same 1,356,186 shares. Item 5 explicitly states this is an ownership of 5 percent or less of a class.
The filing identifies Eventide as organized in Delaware and lists the filers' address as One International Place, Suite 4210, Boston, Massachusetts. The exhibit includes a joint filing agreement executed August 14, 2025, and Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.